Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × belzutifan × 30 days × Clear all

Phase

Phase 3 1 Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Renal Cell 1

Interventions

pembrolizumab 51 Carboplatin 36 Specimen Handling 34 Magnetic Resonance Spectroscopy 30 Biopsy 30 Cyclophosphamide 28 Nivolumab 22 fludarabine 20 venetoclax 19 Gemcitabine 19 Dexamethasone 19 Bevacizumab 19 Paclitaxel 18 Pemetrexed 17 Temozolomide 15 Cisplatin 14 Rituximab 13 Azacitidine 13 atezolizumab 12 Prednisone 12 Lenalidomide 12 Cetuximab 11 Vincristine 10 Fulvestrant 10 Irinotecan 9 fludarabine phosphate 8 durvalumab 8 aldesleukin 8 X-Rays 8 Radiotherapy 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07049926 2026-02-19

MK-3475-03C

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡